Avidity Biosciences Inc. (RNA) Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Avidity Biosciences Inc. (RNA) Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy

Avidity Biosciences Inc. (RNA) Prices 8M Share Offering at $18/sh

August 4, 2021 5:30 AM EDT

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of... More